Screener
Iovance Biotherapeutics, Inc. IOVA Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Amtagvi | $90.72M+67.8% | $60.22M+38.2% | $64.9M+33.2% | $57.48M+36.7% | $54.07M+322% | |
| Proleukin | $8.59M+46.2% | $11.21M+94.8% | $21.87M-12.4% | $9.97M-39.6% | $5.88M-67.9% |
FAQ
- How does Iovance Biotherapeutics, Inc. break its business down?
- Iovance Biotherapeutics, Inc. (IOVA) reports revenue by product across 2 parts — Amtagvi and Proleukin. Each is extracted from the segment footnotes and tracked over time.
- Where does Iovance Biotherapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Iovance Biotherapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
